Literature DB >> 33398346

Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis.

Dingxian Zhu1, Jianjun Qiao1, Shunli Tang1, Yunlei Pan1, Sheng Li1, Changyi Yang1, Hong Fang1.   

Abstract

OBJECTIVES: The present study aimed to determine the correlation between serum carcinoembryonic antigen (CEA) level and the severity of interstitial lung disease (ILD) in clinically amyopathic DM (CADM) patients.
METHODS: We performed a retrospective study including 41 Chinese CADM patients without malignancy. Serum CEA levels, clinical and laboratory findings were collected. Association tests between CEA levels and disease activity parameters were performed.
RESULTS: Among the 41 patients, 16 (39.0%) developed rapidly progressive (RP)-ILD; of them, 14 (87.5%) had elevated serum CEA levels. Multivariate logistic regression analysis indicated that an elevated serum CEA level was an independent risk factor for RP-ILD. The incidence of elevated CEA level was significantly higher in patients with RP-ILD than in those without RP-ILD (87.5 vs 16.0%, P < 0.001). Furthermore, CEA levels were higher in patients with CADM with RP-ILD [26.87 (6.71) μg/l] than in those without RP-ILD [3.23 (0.64) μg/l] (P < 0.001). CEA levels in CADM patients were associated with the ferritin, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase levels, and CT scores of the lungs. Also, elevated CEA levels are related to the organizing pneumonia pattern and lower lung zone consolidation in high-resolution CT. Moreover, the cumulative survival rate was significantly lower (68.4 vs 31.6%, P < 0.001) in the group with a CEA level >8.75 μg/l than that in the group with a CEA level <8.75 μg/l.
CONCLUSIONS: An elevated serum CEA level is common in patients with CADM, and a higher serum CEA level is a powerful indicator of RP-ILD and poor prognosis in those patients.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  carcinoembryonic antigen; clinically amyopathic dermatomyositis; interstitial lung disease; macrophage activation

Year:  2021        PMID: 33398346     DOI: 10.1093/rheumatology/keaa819

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

1.  Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.

Authors:  Fang Chen; Jinping Wang; Puli Zhang; Yu Zuo; Lifang Ye; Guochun Wang; Xiaoming Shu
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

2.  Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department.

Authors:  Keyun Tang; Hanlin Zhang; Hongzhong Jin
Journal:  Front Med (Lausanne)       Date:  2021-12-02

3.  A Matrix Prediction Model for the 6-Month Mortality Risk in Patients With Anti-Melanoma Differentiation-Associated Protein-5-Positive Dermatomyositis.

Authors:  Zhi-Ming Ouyang; Jian-Zi Lin; Ao-Juan Tang; Ze-Hong Yang; Li-Juan Yang; Xiu-Ning Wei; Qian-Hua Li; Jin-Jian Liang; Dong-Hui Zheng; Bing-Peng Guo; Gui Zhao; Qian Han; Lie Dai; Ying-Qian Mo
Journal:  Front Med (Lausanne)       Date:  2022-04-01

4.  Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease.

Authors:  Kai Wang; Yian Tian; Shanshan Liu; Zhongyuan Zhang; Leilei Shen; Deqian Meng; Ju Li
Journal:  Pharmgenomics Pers Med       Date:  2022-09-01

5.  The significance of elevated tumor markers among patients with interstitial lung diseases.

Authors:  Byoung Soo Kwon; Eun Sun Kim; Sung Yoon Lim; Myung Jin Song; Yeon Wook Kim; Hyung-Jun Kim; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Jae Ho Lee
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.